Details for Patent: 8,852,632

« Back to Dashboard

Which drugs does patent 8,852,632 protect, and when does it expire?

Patent 8,852,632 protects ISENTRESS and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: 8,852,632

Title:	Pharmaceutical formulation containing a release rate controlling composition
Abstract:	Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R1, R2, R3 and R4 are defined herein. The formulations are suitable for use in the inhibition of HIV integrase, the treatment and prophylaxis of HIV infection, and the treatment, prophylaxis and delay in the onset of AIDS.
Inventor(s):	Nazaneen Pourkavoos, James R. Ney, Maria T. Cruanes, Yunhui Wu, Saurabh A. Palkar
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US11/792,118
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process; Dosage form;

Drugs Protected by US Patent 8,852,632

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007	AB	RX	Yes	Yes			Y	Y		TREATMENT OF HIV INFECTION

International Family Members for US Patent 8,852,632

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005311652
Brazil	PI0518781
Canada	2588445
China	101068550